AWARD NUMBER: W81XWH-12-1-0497

TITLE: Phospholipids as Biomarkers for Excessive Alcohol Use

PRINCIPAL INVESTIGATOR:

Suthat Liangpunsakul, MD

CONTRACTING ORGANIZATION:

Vĩ • c^ • Á - Qã ã æ Á M ã ^ | • ã
 Qã ã æ [| ã Ê Á M Î G E Á

REPORT DATE: 12/1/2014

TYPE OF REPORT: Annual report

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE October 2014		2. REPORT TYPE Annual		3. DATES COVERED 15Sept2013-14Sept2014	
4. TITLE AND SUBTITLE Phospholipids as Biomarkers for Excessive Alcohol Use				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-12-1-0497	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Suthat Liangpunsakul Email: sliangpu@iu.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) . Trustees of Indiana University Indianapolis, IN 46202				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT The study is designed to evaluate the utility of levels of two phospholipids in serum as a marker of past drinking behavior across month-level time horizons, in an attempt to improve ability to measure alcohol quantity consumed and associated damage better than can be done with ethyl alcohol level measures and other existing tests that only measure very recent exposure and poorly reflect quantity consumed. This will be achieved by correlating detailed questionnaire data on alcohol consumption with serum phospholipid levels in subjects not selected for alcohol abuse (part I) and subjects under alcohol abuse treatment (part II). The Department of Defense-funded study will conduct Part I at the VA hospital and Part II at the Fairbanks treatment facility. Part I involves a single study session (n=280), while Part II will involve serial blood draws and phospholipid measures at several treatment visits (n=60). The study is open to 280 subjects for Part I, and 60 subjects for part II. Part I has 179 consented, and 18 screen fails; Part II has 33 consented (one withdrew from the study) and 8 screen fails. The study is currently active and analysis has not been completed. Since the inception of the study, we have not experienced any problems with subjects' recruitment. To date, we have recruited 197 subjects into Part I of the study and 41 subjects into part II.					
15. SUBJECT TERMS- Phospholipids as Biomarkers of Excessive Alcohol Use					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT UU	18. NUMBER OF PAGES 5	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
1. Introduction.....	4
2. Keywords.....	4
3. Overall Project Summary.....	4
4. Key Research Accomplishments.....	4
5. Conclusion.....	4
6. Publications, Abstracts, and Presentations.....	4
7. Inventions, Patents and Licenses.....	5
8. Reportable Outcomes.....	5
9. Other Achievements.....	5
10. References.....	5
11. Appendices.....	n/a

INTRODUCTION:

Our proposal is to determine the diagnostic utility of sphingomyelin (SM) and lysophosphatidylcholine (LPC) as the potential biomarkers to screen for excessive alcohol use (EAU); a rising epidemic reported to be as high as 40% among returning veterans. Drinking becomes excessive when it causes or elevates the risk for alcohol-related problems or complicates the management of other health problems. According to the NIH/NIAAA, excessive drinking is defined as men who drink more than 4 standard drinks in a day (or more than 14 per week) and women who drink more than 3 drinks in a day (or more than 7 per week). Non-civilian military personnel have been deployed in support of the war efforts in Afghanistan (Operation Enduring Freedom, OEF) and Iraq (Operation Iraqi Freedom, OIF) since September 11, 2001. These sustained combat operations have resulted in military personnel experiencing physical threat or actual injury during the deployment and difficult adjustments during post-deployment period. Negative life stress is a major contributor to the onset and exacerbation of EAU. The prevalence of EAU is alarming, and the vigilance and action to identify veterans with EAU is of importance. The consequences of under-detection of EAU, thus delayed intervention are serious because relative risk of alcohol-related health conditions such as cirrhosis, pancreatitis, and hepatocellular carcinoma, is increased with the amounts and duration of alcohol consumed per day. We hypothesize that alcohol consumption elevates a panel of serum phospholipids (sphingomyelin, and lysophosphatidylcholines) in proportion to the level of consumption in the past month. Further, we hypothesize that such relationship can also be identified from a dried blood spot via a finger-stick procedure. The *central objective* of this proposal is to determine the diagnostic values of these two phospholipids as the potential biomarkers for EAU. We plan to recruit subjects to determine the relationship between the panel of serum phospholipids of interest and the amount of alcohol consumption during the past month in returning Indiana OEF/OIF veterans.

KEYWORDS: Excessive alcohol use, phospholipids, biomarkers

OVERALL PROJECT SUMMARY:

Recruitment: Since the inception of the study, we do not experience any problems with subjects' recruitment. To date, we have recruited 273 subjects into Part I of the study and 57 subjects into part II. The total subjects we proposed to recruit are 280 for Part I and 60 for Part II. The recruitment is going well, and that it is not necessary to change the recruitment protocol. We do not anticipate any problems or delay. The next step after the completion of recruitment is to perform analysis of these samples – which can be accomplished in the next 12-18 months.

KEY RESEARCH ACCOMPLISHMENTS: Nothing to report at this stage

CONCLUSION: Our project is significant to military personnel including the veterans. If successful, we expect to identify the non-invasive markers that can be used in clinical practice to screen for excessive alcohol use.

PUBLICATIONS, ABSTRACTS, AND PRESENTATIONS:

I would like to thank the DoD for support of my research. Because of the protected time that I received, I would be able to use this time to publish several papers (cited the DoD support) below.

1: Chayanupatkul M, Liangpunsakul S. Cirrhotic cardiomyopathy: review of pathophysiology and treatment. *Hepatol Int.* 2014 Jul;8(3):308-315. PubMed PMID: 25221635; PubMed Central PMCID: PMC4160726.

2: Jinjuvadia R, Liangpunsakul S; for the Translational Research and Evolving Alcoholic Hepatitis Treatment Consortium. Trends in Alcoholic Hepatitis-related Hospitalizations, Financial Burden, and Mortality in the United States. J Clin Gastroenterol. 2014 Jun 25. [Epub ahead of print] PubMed PMID: 25198164.

3: Aggarwal A, Puri K, Liangpunsakul S. Deep vein thrombosis and pulmonary embolism in cirrhotic patients: systematic review. World J Gastroenterol. 2014 May 21;20(19):5737-45. doi: 10.3748/wjg.v20.i19.5737. PubMed PMID: 24914335; PubMed Central PMCID: PMC4024784.

4: Chayanupatkul M, Liangpunsakul S. Alcoholic hepatitis: a comprehensive review of pathogenesis and treatment. World J Gastroenterol. 2014 May 28;20(20):6279-86. doi: 10.3748/wjg.v20.i20.6279. PubMed PMID: 24876748; PubMed Central PMCID: PMC4033465.

5: Zhou P, Ross RA, Pywell CM, Liangpunsakul S, Duffield GE. Disturbances in the murine hepatic circadian clock in alcohol-induced hepatic steatosis. Sci Rep. 2014 Jan 16;4:3725. doi: 10.1038/srep03725. PubMed PMID: 24430730; PubMed Central PMCID: PMC3893658.

INVENTIONS, PATENTS AND LICENSES: N/A

REPORTABLE OUTCOMES: Nothing to report at this time

OTHER ACHIEVEMENTS: Nothing to report

If you have any questions or concerns, please do not hesitate to contact me.

Sincerely,

A handwritten signature in black ink, appearing to read 'Suthat Liangpunsakul', followed by a horizontal line.

Suthat Liangpunsakul, MD, MPH
Associate Professor of Medicine
Division of Gastroenterology and Hepatology
Department of medicine
Indiana University School of Medicine

Adjunct, Associate Professor of Public Health
Department of Public Health
Indiana University Purdue University Indianapolis